Abstract
BackgroundHigh-grade gliomas are one of the most invasive and therapy-resistant cancers. We have recently shown that noncanonical NF-κB/RelB signaling is a potent driver of tumorigenesis and invasion in the aggressive, mesenchymal subtype of glioma. However, the relevant signals that induce activation of noncanonical NF-κB signaling in glioma and its function relative to the canonical NF-κB pathway remain elusive.MethodsThe ability of tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) to regulate NF-κB signaling and promote tumor progression was investigated in both established and primary high-grade glioma tumor lines using a three-dimensional (3-D) collagen invasion assay. The roles of specific NF-κB proteins in regulating glioma cell invasion and expression of Matrix Metalloproteinase 9 (MMP9) in response to TWEAK were evaluated using shRNA-mediated loss-of-function studies. The ability of NF-κB-inducing kinase (NIK) to promote glioma growth in vivo was investigated using an orthotopic xenograft mouse model.ResultsIn glioma cells that display elevated noncanonical NF-κB signaling, loss of RelB attenuates invasion without affecting RelA expression or phosphorylation and RelB is sufficient to promote invasion in the absence of RelA. The cytokine TWEAK preferentially activates the noncanonical NF-κB pathway through induction of p100 processing to p52 and nuclear accumulation of both RelB and p52 without activating the canonical NF-κB pathway. Moreover, TWEAK, but not TNFα, significantly increases NIK mRNA levels. TWEAK also promotes noncanonical NFκB-dependent MMP9 expression and glioma cell invasion. Finally, expression of NIK is sufficient to increase gliomagenesis in vivo.ConclusionsOur data establish a key role for NIK and noncanonical NF-κB in mediating TWEAK-induced, MMP-dependent glioma cell invasion. The findings also demonstrate that TWEAK induces noncanonical NF-κB signaling and signal-specific regulation of NIK mRNA expression. Together, these studies reveal the important role of noncanonical NF-κB signaling in regulating glioma invasiveness and highlight the therapeutic potential of targeting activation of NIK in this deadly disease.Electronic supplementary materialThe online version of this article (doi:10.1186/s12943-014-0273-1) contains supplementary material, which is available to authorized users.
Highlights
High-grade gliomas are one of the most invasive and therapy-resistant cancers
We have previously demonstrated that the noncanonical Nuclear factor kappa B (NF-κB) protein, RelB, is highly expressed in a subset of aggressive, mesenchymal glioma, where it is a potent driver of oncogenesis and a predictor of survival in human patients [17]
We investigate the effects of TNF-like weak inducer of apoptosis (TWEAK) on noncanonical NF-κB/RelB signaling, Matrix Metalloproteinase 9 (MMP9) expression and glioma invasion
Summary
High-grade gliomas are one of the most invasive and therapy-resistant cancers. We have recently shown that noncanonical NF-κB/RelB signaling is a potent driver of tumorigenesis and invasion in the aggressive, mesenchymal subtype of glioma. The relevant signals that induce activation of noncanonical NF-κB signaling in glioma and its function relative to the canonical NF-κB pathway remain elusive. Aberrant activation of the canonical NF-κB pathway is well documented in a variety of malignancies [1,2] and plays important roles in regulating glioma invasion and tumor progression [3,4,5]. NF-κB proteins are evolutionarily conserved transcription factors that play central roles as coordinators of key biological processes, including immunity, inflammation, cell death and survival. In response to specific extracellular signals such as the cytokine tumor necrosis factor-α (TNFα), activation of canonical NF-κB signaling is triggered by signal-induced phosphorylation and degradation of IκBα, followed by nuclear translocation of the active, liberated RelA-p50 complexes. IκBα phosphorylation-induced degradation and activation of the canonical NF-κB pathway is dependent on IκB kinase-β (IKKβ)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.